Single-cell atlas of peripheral blood by CyTOF revealed peripheral blood immune cells metabolic alterations and neutrophil changes in intracranial aneurysm rupture

Abstract

Previous studies have found that the peripheral immune environment is closely related to the occurrence and development of intracranial aneurysms. However, it remains unclear how the metabolism of peripheral blood mononuclear cells (PBMCs) and the composition of polymorphonuclear leukocytes (PMNs) changes in the process of intracranial aneurysm rupture. This study utilized cytometry by time of flight technology to conduct single-cell profiling analysis of PBMCs and PMNs from 72 patients with IAs. By comparing the expression differences of key metabolic enzymes in PBMCs between patients with ruptured intracranial aneurysms (RIAs) and unruptured intracranial aneurysms, we found that most PBMCs subsets from RIA group showed upregulation of rate-limiting enzymes related to the glycolytic pathway. By comparing the composition of PMNs, it was found that the proinflammatory CD101+HLA DR+ subsets were increased in the RIA group, accompanied by a decrease in the anti-inflammatory polymorphonuclear myeloid-derived suppressor cells. In conclusion, this study showed the changes in the peripheral immune profile of RIAs, which is helpful for our understanding of the mechanisms underlying peripheral changes and provides a direction for future related research.

Keywords

CyTOF / heterogeneity of neutrophils / immune metabolism / intracranial aneurysms

References

[1] Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: development, rupture and preventive management. Nat Rev Neurol. 2016; 12(12): 699-713.

[2] Maira G, Albanese A, Pentimalli L, Tirpakova B. Treatment of intracranial aneurysms. Clin Exp Hypertens. 2006; 28(3-4): 371-376.

[3] Chalouhi N, Ali MS, Jabbour PM, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012; 32(9): 1659-1676.

[4] Zhang HF, Zhao MG, Liang GB, et al. Dysregulation of CD4(+) T cell subsets in intracranial aneurysm. DNA Cell Biol. 2016; 35(2): 96-103.

[5] Zhang B, Qin Y, Zhao S, et al. Association of elevated neutrophil-to-lymphocyte ratio with increased intracranial aneurysm stability scores and aneurysm growth. J Stroke Cerebrovasc Dis. 2023; 32(4): 107052.

[6] Hallikainen J, Pyysalo M, Keränen S, et al. Systemic immune response against the oral pathogens Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans is associated with the formation and rupture of intracranial aneurysms. Eur J Neurol. 2021; 28(9): 3089-3099.

[7] Kawabata S, Takagaki M, Nakamura H, et al. Dysbiosis of gut microbiome is associated with rupture of cerebral aneurysms. Stroke. 2022; 53(3): 895-903.

[8] Mesko B, Poliska S, Nagy L. Gene expression profiles in peripheral blood for the diagnosis of autoimmune diseases. Trends Mol Med. 2011; 17(4): 223-233.

[9] Ge P, Li H, Ya X, et al. Single-cell atlas reveals different immune environments between stable and vulnerable atherosclerotic plaques. Front Immunol. 2022; 13: 1085468.

[10] Ya X, Ma L, Liu C, et al. Metabolic alterations of peripheral blood immune cells and heterogeneity of neutrophil in intracranial aneurysms patients. Clin Transl Med. 2024; 14(2): e1572.

[11] Artyomov MN, Van den Bossche J. Immunometabolism in the single-cell era. Cell Metab. 2020; 32(5): 710-725.

[12] Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017; 169(4): 570-586.

[13] Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity. 2022; 55(1): 14-30.

[14] Pålsson-McDermott EM, O’Neill LAJ. Targeting immunometabolism as an anti-inflammatory strategy. Cell Res. 2020; 30(4): 300-314.

[15] Baker CJ, Fiore A, Connolly ES Jr, Baker KZ, Solomon RA. Serum elastase and alpha-1-antitrypsin levels in patients with ruptured and unruptured cerebral aneurysms. Neurosurgery. 1995; 37(1): 56-61. discussion 61–2.

[16] Marshman LA. Elastin degradation in the superficial temporal arteries of patients with intracranial aneurysms reflects changes in plasma elastase. Neurosurgery. 1998; 43(4): 982.

[17] Tutino VM, Poppenberg KE, Jiang K, et al. Circulating neutrophil transcriptome may reveal intracranial aneurysm signature. PLoS One. 2018; 13(1): e0191407.

[18] Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020; 20(9): 485-503.

[19] Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol. 2018; 14(8): 467-475.

[20] Sas AR, Carbajal KS, Jerome AD, et al. A new neutrophil subset promotes CNS neuron survival and axon regeneration. Nat Immunol. 2020; 21(12): 1496-1505.

[21] Spitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell. 2016; 165(4): 780-791.

[22] Hartmann FJ, Mrdjen D, McCaffrey E, et al. Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol. 2021; 39(2): 186-197.

[23] Mukhopadhyay M. Metabolic profiling of CD8(+) T cells at the single-cell level. Nat Methods. 2020; 17(11): 1071.

[24] Cossarizza A, Chang HD, Radbruch A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol. 2021; 51(12): 2708-3145. doi:10.1002/eji.202170126

[25] Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2006; 355(9): 928-939.

[26] Schievink WI. Intracranial aneurysms. N Engl J Med. 1997; 336(1): 28-40.

[27] Lawton MT, Vates GE. Subarachnoid hemorrhage. N Engl J Med. 2017; 377(3): 257-266.

[28] Al-Shahi R, White PM, Davenport RJ, Lindsay KW. Subarachnoid haemorrhage. BMJ (Clinical Research ed). 2006; 333(7561): 235-240.

[29] Nakaoka H, Tajima A, Yoneyama T, et al. Gene expression profiling reveals distinct molecular signatures associated with the rupture of intracranial aneurysm. Stroke. 2014; 45(8): 2239-2245.

[30] Palsson-McDermott EM, Curtis AM, Goel G, et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015; 21(1): 65-80.

[31] Yang L, Xie M, Yang M, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun. 2014; 5: 4436.

[32] Wang J, Yang P, Yu T, et al. Lactylation of PKM2 suppresses inflammatory metabolic adaptation in pro-inflammatory macrophages. Int J Biol Sci. 2022; 18(16): 6210-6225.

[33] Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell Biosci. 2019; 9: 52.

[34] Das Gupta K, Shakespear MR, Curson JEB, et al. Class IIa histone deacetylases drive toll-like receptor-inducible glycolysis and macrophage inflammatory responses via pyruvate kinase m2. Cell Rep. 2020; 30(8): 2712-2728. doi:10.1016/j.celrep.2020.02.007 e8

[35] Damasceno LEA, Prado DS, Veras FP, et al. PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation. J Exp Med. 2020; 217(10).

[36] Cope A, Le Friec G, Cardone J, Kemper C. The Th1 life cycle: molecular control of IFN-γ to IL-10 switching. Trends Immunol. 2011; 32(6): 278-286.

[37] Merah-Mourah F, Cohen SO, Charron D, Mooney N, Haziot A. Identification of novel human monocyte subsets and evidence for phenotypic groups defined by interindividual variations of expression of adhesion molecules. Sci Rep. 2020; 10(1): 4397.

[38] Ravenhill BJ, Soday L, Houghton J, Antrobus R, Weekes MP. Comprehensive cell surface proteomics defines markers of classical, intermediate and non-classical monocytes. Sci Rep. 2020; 10(1): 4560.

[39] Wypasek E, Padjas A, Szymańska M, Plens K, Siedlar M, Undas A. Non-classical and intermediate monocytes in patients following venous thromboembolism: links with inflammation. Adv Clin Exp Med. 2019; 28(1): 51-58.

[40] Moretta L. Dissecting CD56dim human NK cells. Blood. 2010; 116(19): 3689-3691.

[41] De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011; 208(3): 469-478.

[42] Wan YY. GATA3: a master of many trades in immune regulation. Trends Immunol. 2014; 35(6): 233-242.

[43] Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018; 18(3): 153-167.

[44] Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013; 497(7448): 217-223.

[45] Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012; 30: 39-68.

[46] McKenna E, Mhaonaigh AU, Wubben R, et al. Neutrophils: need for standardized nomenclature. Front Immunol. 2021; 12: 602963.

[47] Fukushima K, Nabeshima H, Kida H. Revealing the diversity of neutrophil functions and subsets. Cell Mol Immunol. 2021; 18(4): 781-783.

[48] Zhu YP, Eggert T, Araujo DJ, Vijayanand P, Ottensmeier CH, Hedrick CC. CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. J Immunother Cancer. 2020; 8(2).

[49] Sandilands GP, McCrae J, Hill K, Perry M, Baxter D. Major histocompatibility complex class II (DR) antigen and costimulatory molecules on in vitro and in vivo activated human polymorphonuclear neutrophils. Immunology. 2006; 119(4): 562-571.

[50] Gullotta GS, De Feo D, Friebel E, et al. Age-induced alterations of granulopoiesis generate atypical neutrophils that aggravate stroke pathology. Nat Immunol. 2023; 24(6): 925-940.

[51] Davis RE, Sharma S, Conceição J, et al. Phenotypic and functional characteristics of HLA-DR(+) neutrophils in Brazilians with cutaneous leishmaniasis. J Leukocyte Biol. 2017; 101(3): 739-749.

[52] Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021; 6(1): 362.

[53] Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022; 21(1): 184.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.